Lovotibeglogene autotemcel (Lyfgenia) — Clinical Policy
Customize your policy alerts
Sign up for Peach State Health Plan Policy CP.PHAR.627 alerts
Get alerted when Policy CP.PHAR.627 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity and prior authorization criteria for Lyfgenia (lovotibeglogene autotemcel) for patients with sickle cell disease and related administrative guidance for other indications and continued therapy across Peach State Health Plan lines of business.
Added HCPCS code J3394 and removed HCPCS codes J3590 and C9399.
Clarified that only βs/βs genotype genetic confirmation is required and added requirement for documentation of ≥4 severe vaso-occlusive events within the past 24 months.
Revised hydroxyurea failure criterion to require hydroxyurea tried for ≥6 months and removed requirement for ≥1 VOE while on hydroxyurea.
Added criterion requiring documentation of member body weight for verification of weight-based dose.
Clarified minimum Lyfgenia dose required and set approval duration to 6 months to allow for gene therapy preparation; infusion is one-time.
Coverage Criteria
inv-01: Initial Therapy — Sickle Cell Disease — Covered when ALL of the following are met
Covered when ALL of the following are met:
See Appendix D regarding trial population
Myelosuppression alone does not qualify as failure; follow NHLBI guidance for titration
Both attestations (a and b) required
Patients with alpha-thalassemia trait may experience anemia requiring chronic transfusions
See Appendix E for examples of advanced liver disease
Approval duration: 6 months (one-time infusion per lifetime)
inv-03: Initial therapy / Coverage criteria — Covered when ALL of the following are met (policy updates aligned to FDA labeling and trial population)
Covered when ALL of the following are met (policy updates aligned to FDA labeling and trial population):
Approval duration set to 6 months to allow for therapy preparation; infusion is one-time.
inv-02: Continued Therapy — Continuation not authorized
Continuation not authorized:
Approval duration: Not applicable
Requests for use of lovotibeglogene autotemcel (Lyfgenia) for non‑FDA–approved indications are not authorized under this policy unless the provider submits sufficient documentation of efficacy and safety per the plan’s applicable off‑label use policies (for example, CP.CPA.09 for commercial, HIM.PA.154 for marketplace, and CP.PMN.53 for Medicaid).
Coverage is excluded for members with active infections or serious comorbid conditions identified in the approval criteria. Specifically, the member must be documented as negative for active HIV, hepatitis B virus, and hepatitis C virus within the prior 6 months, and must not have advanced liver disease (see Appendix E for examples). The policy also requires the absence of current malignancy and the absence of a current immunodeficiency disorder.
Use of Lyfgenia is not authorized for patients who have a current malignancy or a current immunodeficiency disorder, and is not authorized in clinical settings that do not meet the policy’s listed eligibility and safety criteria (including required infection screening, transplant attestation, prior therapy history, and dosing/cell‑count requirements). The product carries a boxed warning for hematologic malignancy and providers must confirm all listed contraindications and exclusions before initiating therapy.
Inclusion of a procedure or diagnosis code in this policy does not by itself guarantee coverage. Providers must follow current professional coding guidance and submit claims using the appropriate HCPCS/CPT codes (the policy notes use of HCPCS J3394 for lovotibeglogene autotemcel) and supporting clinical documentation to substantiate medical necessity.
Initial Therapy (Sickle Cell Disease)
Initial Therapy — Sickle Cell Disease
Covered when ALL of the following are met:
See Appendix D regarding trial population
Myelosuppression alone does not qualify as treatment failure; NHLBI recommends a 6-month trial on maximum tolerated dose
Both attestations (a and b) required
Patients with alpha‑thalassemia trait may experience anemia requiring chronic transfusions
Advanced liver disease examples in Appendix E
Approval duration: 6 months to allow for gene therapy preparation; infusion is one-time per lifetime
Initial Therapy / Dosing
Initial dosing and administration (must meet dosing requirements):
Dose verification requires documented member body weight in kg
Product administered as a one‑time infusion; approval duration set to 6 months to allow preparation
Approval duration covers preparation period; billing should use HCPCS code J3394 per policy updates
Require ≥6-month trial and failure of hydroxyurea before approval
Members must have documentation of a trial and failure of hydroxyurea at up to the maximally indicated or tolerated dose for at least 6 months prior to authorization, unless hydroxyurea is contraindicated or not tolerated. NHLBI guidance on dosing and escalation (Appendix B) applies and myelosuppression alone does not qualify as treatment failure.
- Trial duration: ≥ 6 months on maximally indicated/tolerated dose
- Exception: documented contraindication or intolerance to hydroxyurea
- Myelosuppression (reversible, dose-dependent) does not count as failure per policy
Continuation / Continued Therapy
inv-26: Continued therapy — Lyfgenia is a one-time therapy; continued therapy is not applicable
Lyfgenia is a one-time therapy; continued therapy is not applicable.
Approval duration: Not applicable
inv-27: Continuation therapy — Post-approval/continuation considerations
Post-approval/continuation considerations
Infusion is one-time per lifetime
Continued therapy not authorized (one‑time infusion only)
Lyfgenia is a one‑time therapy and continued/repeat dosing is not authorized; do not submit requests for ongoing maintenance dosing.
Coding and Billing
Provider Actions and Documentation Requirements
Obtain prior authorization and meet all initial approval criteria
Prior authorization is required and will only be approved if the request meets all listed initial approval criteria, including documented SCD diagnosis with βS/βS genotype confirmation, specialist involvement, age ≥12 years, VOE history, hydroxyurea trial/failure, transplant attestations, infection screening, absence of prior HSCT/gene therapy, and dosing/cell‑count requirements.
Prior authorization plus HCPCS J3394 and supporting clinical documentation
Submit prior authorization with clinical documentation supporting genotype confirmation, history of ≥4 severe VOEs in the past 24 months, prior treatments (including hydroxyurea trial), member body weight, exclusionary infection/liver/malignancy status, and use HCPCS code J3394 for billing lovotibeglogene autotemcel.
- Required billing code: J3394
- Include documentation of VOE history, prior hydroxyurea use, and member weight
Submit office notes, labs, or other clinical records for review
Provider must submit supporting clinical documentation (office chart notes, lab results, or other medical records) showing the member meets all approval criteria; all requests are subject to medical director review.
Document genotype, VOE history, hydroxyurea trial, and member weight
Documentation must include genetic confirmation of βS/βS genotype, history documenting ≥4 severe VOEs in the past 24 months using the pivotal trial definition, record of hydroxyurea tried for ≥6 months if applicable, and the member's body weight in kg to verify weight‑based dosing.
- Genotype confirmation: βS/βS
- ≥4 severe VOEs in past 24 months (per pivotal trial definition)
- Hydroxyurea trial documented ≥6 months if applicable
- Member body weight in kg
Off‑label (non‑FDA) indications require sufficient efficacy/safety documentation
Requests for indications not FDA‑approved under this policy will be denied unless sufficient documentation of efficacy and safety is provided per applicable off‑label use policies.
Insufficient documentation may lead to denial
Failure to provide required clinical documentation—such as genotype confirmation, documentation of ≥4 severe VOEs in the prior 24 months, evidence of a ≥6‑month hydroxyurea trial, or member weight for dosing verification—may result in denial of the prior authorization request.
- Missing genotype confirmation
- Insufficient VOE documentation (≥4 severe VOEs)
- No documentation of ≥6‑month hydroxyurea trial when applicable
- Missing member body weight for dose verification
Site of Care
Prescriber: hematology and transplant specialist involvement and HSCT eligibility attestation required
Prescriptions must be by or in consultation with a hematologist and transplant specialist; the member must be evaluated as clinically stable and eligible to undergo myeloablative conditioning and HSCT per transplant specialist attestation.
- Attestation that member understands risks/benefits of alternatives (e.g., allogeneic HSCT)
- Attestation of clinical stability and eligibility for myeloablative conditioning and HSCT
One‑time infusion with preparation period; no additional site restriction specified here
Policy describes a one‑time infusion with a preparation period and does not specify other site‑of‑care restrictions in this section; ensure scheduling reflects single‑course administration and preparation timeline.
- Therapy is administered as a one‑time infusion
- Approval duration set to 6 months to allow for gene therapy preparation
Step Therapy Requirements
| Step | Requirement | Notes / Documentation |
|---|---|---|
| 1 | ||
| Trial of hydroxyurea at maximally indicated or tolerated dose for ≥ 6 months | ||
| Document duration and dose titration per NHLBI guidance; provide chart notes and labs showing hydroxyurea treatment and monitoring (CBC/WBC/differential/reticulocyte counts). If hydroxyurea is contraindicated or not tolerated, document reason. |
Quantity Limits
Definitions
Background
Lovotibeglogene autotemcel (Lyfgenia) is an autologous hematopoietic stem cell‑based gene therapy approved to treat patients aged ≥ 12 years with sickle cell disease and a history of vaso‑occlusive events. Coverage criteria and revisions align with the pivotal trial population and FDA labeling, requiring genetic confirmation of the βS/βS genotype, documentation of ≥ 4 severe vaso‑occlusive events (VOEs) in the prior 24 months per the trial definition, prior hydroxyurea trial/failure where applicable, and a minimum cell dose of 3 × 10^6 CD34+ cells/kg. The therapy is administered as a one‑time infusion following myeloablative conditioning; approval duration is set to 6 months to allow for therapy preparation.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.